Catalyst Pharma’s Firdapse shows treatment effect in certain patients with myasthenia gravis; shares jump 14%

Catalyst Pharmaceuticals (CPRX +13.7%) perks up on almost a 5x surge in volume in response to its announcement of positive top-line results from an investigator-sponsored study in Italy assessing Firdapse (amifampridine phosphate) for the treatment of patients with myasthenia gravis (MG) with anti-MuSK antibodies, an ultra-rare subpopulation of MG patients.

The company says both co-primary efficacy endpoints in the seven-subject study were met: the change from baseline in QMG score and MG-ADL score. Several secondary endpoints were also met.

CEO Patrick J. McEnany says, “These data announced today should allow us to accelerate our MuSK-MG program over the coming months, as we expect to consult with our external experts and regulatory agencies on a pivotal clinical development plan. I would like to thank Dr. Mantegazza, his associates at Carlo Besta Neurological Institute, and the patients that participated in this important clinical trial.”

Next Page

Be the first to comment

Leave a Reply

Your email address will not be published.